Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
By L. Malcovati, M. D. Porta, C. Pascutto, R. Invernizzi, M. Boni, E. Travaglino, F. Passamonti, L. Arcaini, M. Maffioli, P. Bernasconi and 2 more. Journal of Clinical Oncology, 2005
851 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/b4082d98c09b73e86eff4480028a598a2a3456e0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Hematology
Citations in the corpus
- Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013, methodology): “Retrospective studies found that an elevated serum ferritin significantly worsens the survival of transfusion-dependent MDS patients.(93) This survival decrement was restricted to patients diagnosed with refractory anemias according to the WHO criteria.”
- Revised international prognostic scoring system for myelodysplastic syndromes. (2012, methodology): “The changes from the cutpoints used in the IPSS-R compared with those from the IPSS include (1) separating marrow blasts 5% into 0%-2% and 2- 5%; and (2) providing differing depths of cytopenias; also, as patients with marrow blasts of 10%-20% had similar outcomes as those with 21%-30%; and (3) Tabl”
- Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. (2007, methodology): “The diagnosis before 2002 was made according to the French-AmericanBritish criteria(2); all patients were reclassified according to the WHO classification,(8) as previously reported.(12) Patients with MDS unclassified, patients with chronic myelomonocytic leukemia, and patients with 20% marrow blast”